[go: up one dir, main page]

MA49683A - Anticorps anti-cd8 et leurs utilisations - Google Patents

Anticorps anti-cd8 et leurs utilisations

Info

Publication number
MA49683A
MA49683A MA049683A MA49683A MA49683A MA 49683 A MA49683 A MA 49683A MA 049683 A MA049683 A MA 049683A MA 49683 A MA49683 A MA 49683A MA 49683 A MA49683 A MA 49683A
Authority
MA
Morocco
Prior art keywords
antibodies
Prior art date
Application number
MA049683A
Other languages
English (en)
Inventor
Jason T Giurleo
Dangshe Ma
William Olson
Richard Tavare
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63143411&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49683(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA49683A publication Critical patent/MA49683A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA049683A 2017-07-24 2018-07-23 Anticorps anti-cd8 et leurs utilisations MA49683A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762536239P 2017-07-24 2017-07-24
US201862660902P 2018-04-20 2018-04-20

Publications (1)

Publication Number Publication Date
MA49683A true MA49683A (fr) 2020-06-03

Family

ID=63143411

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049683A MA49683A (fr) 2017-07-24 2018-07-23 Anticorps anti-cd8 et leurs utilisations

Country Status (17)

Country Link
US (4) US10730944B2 (fr)
EP (1) EP3658193A1 (fr)
JP (3) JP7304846B2 (fr)
KR (2) KR20250162627A (fr)
CN (1) CN110997013B (fr)
AU (2) AU2018307744C1 (fr)
BR (1) BR112020001360A2 (fr)
CA (1) CA3070796A1 (fr)
CL (1) CL2020000192A1 (fr)
CO (1) CO2020000680A2 (fr)
IL (2) IL271901B2 (fr)
MA (1) MA49683A (fr)
MX (2) MX2020000916A (fr)
MY (1) MY197688A (fr)
PH (1) PH12020550008A1 (fr)
SG (1) SG11202000073XA (fr)
WO (1) WO2019023148A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904969C (fr) 2013-03-13 2025-06-17 Imaginab, Inc. Constructions génétiques de liaison à l'antigène de cluster de différenciation 8
JP7026613B2 (ja) 2015-08-07 2022-02-28 イマジナブ・インコーポレーテッド 標的分子に対する抗原結合コンストラクト
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
SG11202000073XA (en) 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
CN115209925A (zh) * 2020-01-10 2022-10-18 融合制药公司 持续性免疫疗法
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN111413298A (zh) * 2020-05-27 2020-07-14 深圳市天安至远传感科技有限公司 一种光纤表面等离子体共振传感器、制备方法及检测系统
US20240209089A1 (en) * 2020-07-21 2024-06-27 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. Cd8 binding polypeptide and use thereof
EP4196502A1 (fr) 2020-08-13 2023-06-21 Bristol-Myers Squibb Company Procédés de redirection de l'il-2 vers des cellules cibles d'intérêt
CN114112868B (zh) * 2020-08-26 2024-12-13 上海睿昂基因科技股份有限公司 一种用于监测肿瘤相关免疫微环境的流式细胞术试剂盒及监测方法
KR20230086765A (ko) * 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
WO2022087458A1 (fr) * 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions avec des molécules de liaison à l'antigène cd8 pour moduler la fonction de cellules immunitaires
AU2022206324A1 (en) 2021-01-11 2023-07-20 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
KR20240028975A (ko) * 2021-04-08 2024-03-05 사나 바이오테크놀로지, 인크. Cd8-특이적 항체 구조체들 및 이의 조성물
GB2638094A (en) 2021-05-19 2025-08-13 Asher Biotherapeutics Inc Il-21 Polypeptides And Targeted Constructs
AU2022282609A1 (en) * 2021-05-26 2023-11-30 Oxford Biotherapeutics Ltd Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
CN114230665B (zh) * 2021-06-23 2024-03-22 苏州智核生物医药科技有限公司 CD8α结合多肽及其用途
EP4380604A1 (fr) 2021-08-05 2024-06-12 Go Therapeutics, Inc. Anticorps anti-glyco-muc4 et leurs utilisations
US20250066498A1 (en) 2021-09-03 2025-02-27 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
CN118354789A (zh) 2021-09-03 2024-07-16 Go医疗股份有限公司 抗糖-cMET抗体及其用途
WO2023114949A1 (fr) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Procédés et systèmes de production de particules
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
EP4473097A1 (fr) 2022-02-02 2024-12-11 Sana Biotechnology, Inc. Procédés d'administration et de dosage répétés de particules lipidiques ou de vecteurs viraux et systèmes et utilisations connexes
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
JP2025523846A (ja) 2022-07-11 2025-07-25 ジェヌーヴ インク． サイトカイン融合タンパク質
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
CN115337413B (zh) * 2022-08-08 2023-08-22 中国科学院近代物理研究所 一种针对非小细胞肺癌诊断的放射性分子探针的制备及应用
WO2024040194A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
WO2024044655A1 (fr) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Administration de protéines hétérologues
EP4590688A1 (fr) 2022-09-21 2025-07-30 Sana Biotechnology, Inc. Particules lipidiques comprenant des glycoprotéines fixant des paramyxovirus variants et leurs utilisations
CN115746137A (zh) * 2022-10-13 2023-03-07 华道(上海)生物医药有限公司 一种抗cd8抗体及其应用
WO2024119157A1 (fr) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Particules lipidiques avec cofusogènes et leurs procédés de production et d'utilisation
EP4680641A1 (fr) 2023-03-16 2026-01-21 Itabmed Co., Ltd. Protéines de liaison à l'antigène multispécifiques et leurs utilisations
WO2024220597A2 (fr) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Dosage numérique utilisant des gouttelettes pour détecter un vecteur lentiviral compétent pour la réplication
CN121443743A (zh) 2023-05-23 2026-01-30 赛纳生物技术公司 串联融合剂和相关脂质颗粒
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN119684430A (zh) * 2023-09-22 2025-03-25 深圳华大生命科学研究院 一种抗原多肽、由其制备的抗体及其在检测cd8中的应用
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025128807A1 (fr) 2023-12-13 2025-06-19 Amgen Inc. Composés radiomarqués pour la détection de steap1
WO2025149667A1 (fr) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Conjugués anticorps-médicament et leurs utilisations
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025184529A1 (fr) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Particules virales à présentation fusogène et compositions et procédés associés
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques
CN118745228B (zh) * 2024-07-04 2025-09-23 杭州百凌生物科技有限公司 一种抗cd8抗体及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5428156A (en) 1993-04-02 1995-06-27 Associated Universities, Inc. Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006050058A2 (fr) 2004-10-28 2006-05-11 The General Hospital Corporation Methodes de detection et de therapie de tissus enflammes par immunomodulation
US20080193376A1 (en) 2004-10-28 2008-08-14 The General Hospital Corporation Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation
US8889100B2 (en) 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
WO2008124467A1 (fr) 2007-04-06 2008-10-16 Macrocyclics Ligands d'acide hydroxamique bifonctionnels et procede de synthese associe
PE20091525A1 (es) 2007-12-21 2009-09-25 Schering Corp Agonista del receptor glucocorticoide c-20-c21 sustituido
US20090297439A1 (en) 2008-06-02 2009-12-03 Metheresis Translational Research Sa, Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
BRPI0915582A2 (pt) * 2008-06-06 2016-01-26 Baylor Res Inst anticorpos anto-cd8 que bloqueiam a sensibilização de efetores citotóxicos e levam à geração de células t cd8+ reguladoras
SG185430A1 (en) 2010-06-03 2012-12-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
AU2011349443B2 (en) 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
JP6120416B2 (ja) 2012-01-06 2017-04-26 リンクシス ビー．ヴイ． 細胞標的コンジュゲートを調製するための方法、及び得られる錯体
WO2013138696A1 (fr) 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Complexes de zirconium-89, procédés de marquage de cellules, cellules marquées, kits et leurs procédés d'utilisation
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
KR20150006000A (ko) 2012-05-01 2015-01-15 제넨테크, 인크. 항-pmel17 항체 및 면역접합체
WO2013177055A2 (fr) 2012-05-21 2013-11-28 Genentech, Inc. Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
US20150191543A1 (en) * 2012-08-06 2015-07-09 The Regents Of The University Of California Engineered antibody fragments for targeting and imaging cd8 expression in vivo
CN104704359A (zh) 2012-10-25 2015-06-10 生命科技公司 糖蛋白酶介导位点特异性放射性标记的方法和组合物
EP2740726A1 (fr) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Ligands de récepteurs de la neurotensine
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
WO2014133093A1 (fr) 2013-02-28 2014-09-04 独立行政法人国立がん研究センター Anticorps dirigé contre la fibrine insoluble
CA2904969C (fr) 2013-03-13 2025-06-17 Imaginab, Inc. Constructions génétiques de liaison à l'antigène de cluster de différenciation 8
US20160000946A1 (en) 2013-03-14 2016-01-07 The Board Of Trustees Of The Leland Stanford Junior University Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma
CN105189552B (zh) 2013-03-14 2019-08-02 基因泰克公司 抗b7-h4抗体和免疫缀合物
WO2014200969A2 (fr) 2013-06-10 2014-12-18 Millennium Pharmaceuticals, Inc. Méthodes de traitement du cancer
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
FR3008408B1 (fr) 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
AU2014332442B2 (en) 2013-08-26 2019-12-19 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to Sialyl-Lewis
SG11201603125SA (en) 2013-10-21 2016-05-30 Genentech Inc ANTI-Ly6E ANTIBODIES AND METHODS OF USE
AU2014351611B2 (en) 2013-11-19 2020-04-23 Janssen Biotech, Inc. Humanised anti kallikrein-2 antibody
PE20160712A1 (es) 2013-12-13 2016-07-26 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
PT3131585T (pt) 2014-03-19 2020-10-23 Univ Zuerich Agentes quelantes bifuncionais multidentados para complexação de radionuclídeos em diagnóstico e terapia
KR20170003582A (ko) 2014-05-22 2017-01-09 제넨테크, 인크. 항-gpc3 항체 및 면역접합체
WO2015188934A1 (fr) 2014-06-10 2015-12-17 3B Pharmaceuticals Gmbh Conjugué comprenant un ligand de récepteur de neurotensine et son utilisation
CA2949982A1 (fr) 2014-06-11 2015-12-17 Genentech, Inc. Anticorps anti-lgr5 et leurs utilisations
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
JP6945444B2 (ja) 2014-08-08 2021-10-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｐｄ−１薬剤とその使用方法
CN113698485A (zh) 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
SG11201701627PA (en) 2014-09-12 2017-03-30 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
MX2017003126A (es) 2014-09-12 2017-08-28 Genentech Inc Anticuerpos anti-her2 e inmunoconjugados.
CN104360049B (zh) 2014-09-22 2016-08-17 重庆医科大学附属儿童医院 一种t淋巴细胞免疫分型的方法和试剂盒
ES2745848T3 (es) 2014-10-16 2020-03-03 Univ Melbourne Composición novedosa de diagnóstico por imágenes y usos de la misma
CA2969067A1 (fr) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Nouveaux polypeptides fixant pd-l1 pour l'imagerie
US11534506B2 (en) 2015-03-06 2022-12-27 Mayo Foundation For Medical Education And Research Methods for cell labeling and medical imaging
NL2014423B1 (en) 2015-03-09 2016-10-13 Linxis B V Method for removing weakly bound functional moieties from cell targeting conjugates.
EP4218833A1 (fr) 2015-10-01 2023-08-02 Whitehead Institute for Biomedical Research Marquage d'anticorps
US20180326102A1 (en) 2015-11-18 2018-11-15 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
HRP20210644T8 (hr) 2016-05-19 2021-06-25 Bristol-Myers Squibb Company Imunomodulatori za pet-snimanje
EP3463578A1 (fr) 2016-06-06 2019-04-10 LinXis B.V. Conjugués de ciblage de cellules
US11179484B2 (en) 2016-06-24 2021-11-23 University Of Iowa Research Foundation Compositions and methods of treating melanoma
EP3266465A1 (fr) 2016-07-06 2018-01-10 Julius-Maximilians-Universität Würzburg Complexes immuns
CA3031076C (fr) 2016-07-18 2023-10-03 Wisconsin Alumni Research Foundation Agents radiohalogenes pour vaccination contre le cancer immunomodulee in situ
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
US11168148B2 (en) 2016-09-07 2021-11-09 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
EP3515495A4 (fr) 2016-09-26 2020-08-26 Ensemble Group Holdings Procédés d'évaluation et de traitement du cancer chez des sujets ayant des systèmes lymphatiques dysrégulés
WO2018128664A2 (fr) 2016-10-20 2018-07-12 The University Of North Carolina At Chapel Hill Composés marqués au 18f pour l'imagerie tep, et utilisations associées
US11266639B2 (en) 2016-11-07 2022-03-08 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers
SG11202000073XA (en) 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof

Also Published As

Publication number Publication date
US20230159639A1 (en) 2023-05-25
JP7304846B2 (ja) 2023-07-07
AU2018307744C1 (en) 2026-01-29
JP7746334B2 (ja) 2025-09-30
WO2019023148A1 (fr) 2019-01-31
CN110997013B (zh) 2022-09-20
KR102880156B1 (ko) 2025-11-05
MY197688A (en) 2023-07-05
IL271901B1 (en) 2024-11-01
CO2020000680A2 (es) 2020-01-31
SG11202000073XA (en) 2020-02-27
US10730944B2 (en) 2020-08-04
JP2026009919A (ja) 2026-01-21
US20240409637A1 (en) 2024-12-12
AU2018307744A1 (en) 2020-02-13
US11525001B2 (en) 2022-12-13
KR20250162627A (ko) 2025-11-18
EP3658193A1 (fr) 2020-06-03
MX2024014445A (es) 2024-12-06
US12077587B2 (en) 2024-09-03
IL271901A (en) 2020-02-27
CL2020000192A1 (es) 2020-08-14
IL316355A (en) 2024-12-01
CN110997013A (zh) 2020-04-10
CA3070796A1 (fr) 2019-01-31
JP2020534250A (ja) 2020-11-26
US20210147542A1 (en) 2021-05-20
AU2025213570A1 (en) 2025-09-11
IL271901B2 (en) 2025-03-01
PH12020550008A1 (en) 2020-10-12
BR112020001360A2 (pt) 2020-08-11
MX2020000916A (es) 2020-09-10
JP2023121798A (ja) 2023-08-31
AU2018307744B2 (en) 2025-08-14
US20190023790A1 (en) 2019-01-24
KR20200031645A (ko) 2020-03-24

Similar Documents

Publication Publication Date Title
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3661965A4 (fr) Anticorps anti-cd47 et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3898691A4 (fr) Anticorps trem2 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
EP3733702A4 (fr) Anticorps anti-lag-3 et utilisations associées
EP3672987A4 (fr) Anticorps anti-apéline et leurs utilisations